Pneumagen

About:

Pneumagen develops glycan targeted carbohydrate binding modules (CBMs) for respiratory tract infections ) and cancer.

Top Investors: Scottish Enterprise, Equity Gap, Thairm Bio, Scottish Investment Bank, Esperante Ventures

Description:

Pneumagen focuses on developing glycan targeted carbohydrate-binding modules (CBMs) as a new universal therapeutic modality for the treatment of respiratory tract infections (RTIs) and cancer. Founded in 2016, the Company is a spin-out from the University of St Andrews in Scotland and has access to world-class scientific expertise and capabilities in glycobiology.

Total Funding Amount:

18.3M GBP

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Saint Andrews, Fife, United Kingdom

Founded Date:

2016-01-01

Contact Email:

info(AT)pneumagen.com

Founders:

Garry Taylor, Helen Connaris

Number of Employees:

11-50

Last Funding Date:

2023-06-01

IPO Status:

Private

Industries: